Precision BioSciences Advances Gene Editing Trials with Key Milestones in HBV and DMD Programs
Event summary
- Precision BioSciences advanced PBGENE-HBV into new cohorts in the ELIMINATE-B trial and activated the first clinical site for the FUNCTION-DMD trial.
- The company reported $125.8 million in cash, cash equivalents, and restricted cash as of March 31, 2026, with a projected runway through 2028.
- Precision received a $7.5 million clinical milestone cash payment from TG Therapeutics in April 2026.
- PBGENE-HBV will present first evidence of cccDNA elimination at the EASL Congress 2026.
- PBGENE-DMD received FDA Fast Track designation and is actively enrolling patients at Arkansas Children’s Hospital.
The big picture
Precision BioSciences is positioning itself as a leader in gene editing with its ARCUS platform, targeting high-unmet-need diseases like chronic hepatitis B and Duchenne muscular dystrophy. The company's strategic focus on disciplined execution and milestone-driven development aligns with broader industry trends toward precision medicine and curative therapies. With a robust cash position and key regulatory designations, Precision is well-positioned to capitalize on the growing demand for innovative gene editing solutions.
What we're watching
- Clinical Data Impact
- How the upcoming clinical data presentations for PBGENE-HBV and PBGENE-DMD will influence investor confidence and regulatory pathways.
- Execution Risk
- Whether Precision BioSciences can sustain its operational discipline and meet key milestones through 2028 with its current cash runway.
- Partnership Dynamics
- The pace at which Precision BioSciences can leverage its partnerships with TG Therapeutics, Imugene Limited, and iECURE to advance its pipeline.
Related topics